Compare

Revvity/$RVTY

1D1W1M3M6MYTD1Y5YMAX

About Revvity

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Ticker
$RVTY
Sector
Health
Primary listing
NYSE
Employees
11,000

Revvity Metrics

BasicAdvanced
$17B
67.09
$2.26
1.09
$0.28
0.18%

What the Analysts think about Revvity

Analyst ratings (Buy, Hold, Sell) for Revvity stock.
Analyst projections of the future price of Revvity stock.

Bulls say / Bears say

Revvity lifted its 2026 organic-growth outlook to about 5% and its adjusted EPS range to $5.40–$5.45 after a strong third quarter. It also raised its margin outlook for the third time this year, pointing to improving demand and cost savings. (Investing.com)
Diagnostics is a strong growth engine: it delivered 11% organic growth in Q2, while Revvity’s new certified screening test extends its range into early detection of type 1 diabetes. That could broaden the company’s reach in newborn and childhood screening. (Revvity, Revvity)
AI-led drug discovery could create fresh demand for Revvity’s lab tools: management reported rising AI-related orders and an instrument backlog above normal, with demand for high-content screening outpacing near-term production capacity. (The Motley Fool)
Life Sciences remained weak in Q2, with organic revenue down 3%; Signals software fell about 20% as contract timing and tough comparisons weighed on the segment. A slow software recovery could offset growth elsewhere. (Reuters)
Some recent profit gains may not be repeatable: Q2 adjusted EPS included about $0.11 from tariff refunds, and management said some Q3 timing benefits would not recur in Q4. That makes the underlying pace of earnings improvement less clear. (Revvity, Investing.com)
The shares trade near their 52-week high and at a reported P/E of about 72.5, leaving little room for missed targets or a slower recovery in pharma and biotech spending. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.

Revvity Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Revvity Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.